In our weekly check, Kymera Therapeutics, Inc. is graded F (A to F). Of 18 checks on debt, profit, cash flow and trend: 5 pass, warnings: 1, red flags: 12.
Sector: Healthcare · Biotechnology
Next earnings report: 2026-11-03
PTGX · ARWR · AXSM · TGTX · PRAX · KRYS
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks graded D or F lost a third of their value 2-3 times as often as those graded A or B.
Updated 2026-10-03